A team of Yale researchers recently published promising results from a clinical trial testing the effectiveness of a new ...

Seven patients received a peptide containing a neoantigen derived from a cancer driver mutation, which was found to be highly immunogenic. Five patients received the vaccine with subcutaneous ...

"These results support the feasibility of creating a highly immunogenic personalized neoantigen vaccine in a lower mutation burden tumor and are encouraging, though larger-scale studies will be ...

An early-phase trial found that a personalized vaccine targeted and destroyed cancer cells in nine patients with advanced kidney cancer, effectively wiping out the disease and keeping it at bay ...

Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional ...

Each participant received four pools of up to five synthetic long peptides ... of [personalized cancer vaccines] highlights the potential beneficial role for these neoantigen-targeting vaccines ...

“We believe this work can form a foundation for the development of neoantigen vaccines in kidney cancer,” said Braun.

One such approach helps our bodies spot the distinct proteins generated by cancer cells as they mutate, known as neoantigens. “Neoantigen vaccines are personalized cancer treatments that train ...

In our continuing efforts to rationally design effective vaccines, we have taken ... binding epitope (266–296). All four peptide sequences inhibited tumor cell proliferation.